Enhabit, Inc.

NYQ: EHAB
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Enhabit, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get EHAB Z-Score →

About Enhabit, Inc.

Healthcare Medical Care Facilities
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.

📊 Fundamental Analysis

Enhabit, Inc. demonstrates a profit margin of -0.4%, which is below the sector average, suggesting competitive pressure.

The company recently reported 4.7% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is -0.5%, which indicates that capital utilization is currently under pressure.

At a current price of $13.98, EHAB currently trades near the top of its 52-week range (97%) (Range: $6.47 - $14.22).

🏥 Financial Health

🔴 Profit Margin Weak
🔴 Debt/Equity Elevated
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap
$709.11M
Trailing P/E
--
Forward P/E
22.51
Beta (5Y)
1.08
52W High
$14.22
52W Low
$6.47
Avg Volume
1.44M
Day High
Day Low
Get EHAB Z-Score on Dashboard 🚀